SimBioSys®, a clinical AI company pioneering the use of spatial biophysics to advance precision in breast cancer treatment, has entered into a strategic, non-exclusive distribution agreement with Ricoh 3D for Healthcare, LLC, a wholly owned subsidiary of Ricoh USA, Inc. (“Ricoh”). The collaboration aims to expand market access to TumorSight™ Viz, SimBioSys’ FDA-cleared 3D surgical visualization platform designed to enhance breast cancer surgical planning.
TumorSight™ Viz transforms standard breast MRI scans into interactive 3D visualizations that clearly show tumor size, location, and orientation within surrounding tissue. By delivering a more complete picture of tumor anatomy, the platform enables surgeons to make better-informed, patient-specific surgical decisions. The latest version, TumorSight Viz 1.3, is recognized for its high segmentation accuracy, rapid case turnaround, and seamless integration with hospital PACS systems, helping streamline surgical planning and care coordination.
The distribution partnership builds on the recent FDA 510(k) clearance of TumorSight Viz 1.3 and highlights a joint commitment to scaling advanced digital health technologies across the healthcare landscape. By combining SimBioSys’ cutting-edge AI platform with Ricoh’s extensive healthcare expertise, clinical partnerships, and nationwide reach, the two companies are well positioned to accelerate the adoption of AI-powered surgical visualization tools in breast cancer care.
Also Read: eClinicalWorks & Healow Genie Enhance Care & Efficiency with AI
“At SimBioSys, we’re focused on delivering innovation that empowers clinicians to make more precise, personalized surgical decisions,” said Stacey Stevens, President and CEO, SimBioSys. “Ricoh’s reach, reputation, and commitment to advancing surgical innovation make them an ideal partner to help bring TumorSight Viz to more clinical teams and patients. This partnership enables us to meet the increasing demand for tools that help improve outcomes, reduce variability, and elevate the surgical experience for both providers and patients.”
“Breast surgeons are tasked with planning procedures that not only remove tumors effectively but also preserve quality of life for their patients,” said Derek Mathers, Director of Clinical Applications, Ricoh 3D for Healthcare. “At Ricoh, we are committed to advancing patient-specific solutions that support physicians in this balance. Through our collaboration with SimBioSys, TumorSight Viz brings new clarity to surgical planning empowering oncoplastic techniques that expand breast-conserving options and help deliver more consistent outcomes for patients.”
